Incidence and risk factors for neuropsychiatric events among Ghanaian HIV patients on long-term non-nucleoside reverse transcriptase inhibitor-based therapy

Fred S. Sarfo, Maame A. Sarfo, David Chadwick

Kwame Nkrumah University of Science & Technology, Kumasi, Ghana
The James Cook University Hospital, Middlesbrough, UK

ARTICLE INFO

Article history:
Received 17 October 2015
Received in revised form 26 December 2015
Accepted 28 December 2015
Available online 7 January 2016

Keywords:
Africa
HIV
Neuropsychiatric toxicity
NNRTI

ABSTRACT

Background: Non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy (ART) is associated with neuropsychiatric toxicity. Little is known about the risk of short- and long-term neuropsychiatric toxicity in sub-Saharan Africa, where NNRTIs are widely used in first-line combination ART. This observational study assessed the risk of neuropsychiatric toxicity in Ghanaian patients starting first-line ART between 2004 and 2010 at a single centre.

Methods: In this retrospective observational study, frequencies of documented neuropsychiatric toxicity events were assessed and time to events calculated using a Kaplan–Meier analysis. Associations of neuropsychiatric toxicity with specific NNRTIs and other explanatory variables were examined using Cox proportional hazards modelling.

Results: Of 3999 patients initiating NNRTI-based ART, who were followed for a median of 30 (0.25–90) months (11,237 person years), 218 (5.5%) reported symptoms of neuropsychiatric toxicity at a rate of 21.4 events per 1000 person-years (95% CI, 18.8–24.2/1000 py). Events were more common with efavirenz than nevirapine (7.6% versus 2.4%), were usually reported within the first 2 months of ART initiation and persisted up to 84 months in a few patients. The most commonly reported neuropsychiatric adverse drug reactions were insomnia (50%), headaches (8%), dizziness (7%) and abnormal dreams (6%). The factors independently associated with neuropsychiatric toxicity were BMI < 16 kg/m² (aHR of 1.44 [95% CI, 1.02–2.03]) and use of efavirenz (aHR 3.29 [95% CI, 2.32–4.69]). Substitution of NNRTI on account of toxicity was reported in up to 17% of patients experiencing neuropsychiatric events.

Conclusions: NNRTI-related neuropsychiatric toxicity, mainly due to efavirenz, was infrequently documented in this Ghanaian cohort under routine clinical care settings. Regimens with more favourable tolerability will be needed as first-line agents in sub-Saharan Africa in the coming years.

© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Background

The introduction of antiretroviral therapy (ART) for the management of HIV has led to significant reductions in morbidity and mortality. In sub-Saharan Africa where nearly 65% of the 34 million HIV-infected individuals reside, there has been a massive rollout of ART over the last decade. ART is administered through national programs and first-line therapy usually comprises a dual backbone of a nucleoside reverse transcriptase inhibitor (NRTI) and a first generation non-nucleoside reverse transcriptase inhibitor (NNRTI), efavirenz or nevirapine [1]. First-line ART has been reported to be effective and durable in these settings, its durability determined predominantly by the efficacy and tolerability of the regimens chosen [2,3]. The virological efficacy of efavirenz-based ART has until recently been shown to be equivalent or superior to all comparators but for its frequent neuropsychiatric toxicity [4].

A WHO-led survey in 2008 revealed that most national programs in sub-Saharan Africa favoured nevirapine over efavirenz due to cost differentials and availability of fixed combinations of nevirapine [5]. However, a recent WHO-led recommendation gives preference to efavirenz over nevirapine due mainly to skin rash and hepatotoxicity from the latter [6]. Thus, it is expected that use of efavirenz will become more widespread across the continent. However, patients from sub-Saharan Africa frequently harbour single nucleotide polymorphisms predisposing them to higher plasma concentrations of efavirenz with the possibility of developing more frequent neuropsychiatric toxicity and subsequent discontinuation of therapy. We have recently shown in a large
Ghanaian cohort that variants in the CYP2B6*516G > T and *983 T > C were frequent and were marginally associated with increased risk for central nervous system (CNS) toxicity, and importantly influenced the risk for immunological failure [7]. However, very few studies have assessed the risk of neuropsychiatric toxicity over long-term use in sub-Saharan Africa where the HIV burden is highest and ART use is exponentially increasing. The aim of this study was to determine the frequency and determinants of neuropsychiatric toxicity on NNRTI-based ART among Ghanaians.

2. Methods

Ethical permission for this study was provided by the Committee on Human Research Publications and Ethics of the Kwaame Nkrumah University of Science and Technology and the Komfo Anokye Teaching Hospital (KATH), Kumasi, Ghana (ref: CHRPE/AP/073/13). Our institutional review board waived the need for a written informed consent since this was a retrospective, observational study and anonymised data were collected from patients’ records. Since 2004, patients referred to the HIV clinic in KATH, Kumasi have been treated as part of the National AIDS Control Program. Patients were referred from a large area of central and northern Ghana and, after starting ART, were reviewed at weeks 2, 4, 6 and 8, then 2 monthly for the first year and then every 6 months subsequently. HIV viral load was not available routinely and testing for HIV-2 and hepatitis B (HBV) co-infection has been performed only in limited circumstances. The criteria for starting ART in Ghana followed the WHO guidelines [1], with a change of the CD4 threshold for initiation from 200 to 350 cells/mm³ in 2008. First-line ART comprised lamivudine plus either zidovudine or stavudine, plus either nevirapine or efavirenz. The choice between the use of either zidovudine or stavudine was determined by availability but zidovudine was avoided in patients with haemoglobin below 10 g/dL. For NNRTIs, nevirapine tended to be used preferentially in women of child-bearing age. Data on patients’ response to ART including adverse side effects are routinely sought for and documented in case notes at each clinic appointment.

Neuropsychiatric symptoms associated with use of NNRTIs were routinely recorded without any standardised assessment of severity. Individual neuropsychiatric symptoms recorded in patients’ records for which the attending clinician attributed to NNRTI were noted. For statistical analysis, the primary outcome was time to occurrence of Neuropsychiatric toxicity on ART. The cumulative incidence of neuropsychiatric toxicity was calculated using the Kaplan–Meier methodology and the median time to occurrence of the first event calculated using the Mann–Whitney’s U-test, when the median time could not be determined by Kaplan–Meier methodology. Patients were censored either at the date of first CNS toxicity, at the last visit for patients that died, were transferred out or were lost to follow-up and at December 31, 2011 for the remainder. Patients on NNRTIs who were switched to second-line ART regimens due to either clinical or immunological failure were censored at the date of switching and defined as having experienced no specific first-line drug-related toxicity event. A risk factor analysis was performed using multivariate Cox proportional hazards regression model. Collinearity between variables was assessed. A backward selection method was used, retaining those variables with p-values < 0.10 in the final model. The level of significance was set at p < 0.05. All analyses were performed using SPSS version 17.

3. Results

Baseline characteristics and incidence of neuropsychiatric adverse drug reactions: A total of 3999 patients initiating ART were followed for a median (range) of 30 (0.25–90) months and provided 11,236.8 person years on ART. Prior to initiation of ART, patients who subsequently developed neuropsychiatric toxicity compared with those who did not were significantly older and likely to have started efavirenz compared with nevirapine (Table 1).

Two hundred and eighteen (218) patients experienced a total of 235 events of neuropsychiatric toxicity during follow-up, giving 21.4 events per 1000 person-years (95% CI, 18.8–24.2/1000 person years). A total of 203 patients had one event, 13 patients experienced 2 events and 2 patients experienced 3 episodes of neuropsychiatric events during follow-up. Thus, the frequency of reported neuropsychiatric toxicity was 5.5% (n = 3999) with 7.6% (n = 2376) of efavirenz recipients and 2.4% (n = 1623) of nevirapine recipients experiencing an event. The median (range) time to first report of neuropsychiatric toxicity was 2 months (2–84 months). Most neuropsychiatric toxicities were reported in the first year of therapy after which the incidence of events declined, as shown in Fig. 1.

A total of 195 events were reported among patients on efavirenz-based ART compared to 40 events among those on nevirapine-based ART, odds ratio of 3.54 (2.50–5.00), p < 0.0001. A total of 252 neuropsychiatric symptoms were reported, the most common being insomnia (126), headaches (19), dizziness (17), abnormal dreams (14) and drowsiness (13), as shown in Table 2. Insomnia, headaches, abnormal dreams and drowsiness were significantly more common among patients on efavirenz-based ART compared with nevirapine-based ART. Other notable but rarely reported NNRTI-related neuropsychiatric toxicities included cerebellar ataxia (n = 2), dysarthria (n = 5) and seizures (n = 3). Cranial computed tomography scans were performed in the 3 reported cases of seizures and 2 cases of cerebellar ataxia but all were found to be normal.

3.1. Risk factors for neuropsychiatric toxicity

Predictor variables included in univariate analysis of baseline risk factors for neuropsychiatric toxicity included gender, age, body mass index (BMI), CD4 count, WHO clinical stage, HBV sero-status and NNRTI on which the patient developed toxicity. As shown in Table 3, the factors associated with neuropsychiatric toxicity included age ≥ 35 years at initiation of therapy with a hazard ratio (HR) (95% CI) of 1.55 (1.16–2.00), p = 0.003, BMI < 16 kg/m² with HR of 1.45 (1.03–2.04), p = 0.04 and use of efavirenz with HR of 3.43 (2.16–5.72), p < 0.0001. Furthermore, on multivariate analysis, BMI < 16 kg/m² and use of efavirenz were significantly associated with the risk of developing neuropsychiatric toxicity on ART with HR of 1.44 (1.02–2.03), p = 0.04 and 3.29 (2.32–4.69), p < 0.0001, respectively. A total of 33 of 195 events (17%) among patients on efavirenz-based ART led to substitution of efavirenz by nevirapine while 6 of 40 (15%) events among patients on nevirapine-based ART led to substitution of nevirapine by efavirenz (n = 5) and neflavinir (n = 1). The substitutions of nevirapine by efavirenz simultaneously with report of neuropsychiatric events were performed in 5 patients due to their being initiated on anti-tuberculous therapy at the time when those toxicities occurred. This was to avoid drug interactions between nevirapine and rifampicin, which is used as a component of the quadruple anti-tuberculous drug regimen. However, most neuropsychiatric symptoms resolved under continual therapy without having to alter NNRTI dosage on account of neuropsychiatric toxicity.

4. Discussion

This is the first longitudinal study to evaluate in a retrospective cohort the frequencies of neuropsychiatric toxicity among Ghanaians. Neuropsychiatric toxicity due to NNRTI use has predominantly been reported among efavirenz recipients with a frequency ranging from 25% to 70% in various studies [8–12]. In this cohort, the reported frequency of neuropsychiatric toxicity on efavirenz was 7.6% while that on nevirapine was 2.4%, low overall frequencies compared with other reports. However, a similar retrospective study conducted among 2920 patients who initiated Efavirenz-based ART in Jos, Nigeria in an ART treatment program between 2004 and 2011 reported a rate of neuropsychiatric events rate of 29.9 per 1000 person-years of treatment [13] comparable
to 21.4 per 1000 person-years in the present study. Since most neuropsychiatric toxicities are mild to moderate and resolve after the first few weeks of therapy [8–14], mild and transient events may not have been reported although physicians evaluating patients assessed side effects at each visit. Also of interest was the relatively low prevalence of dizziness and mood disorders in this cohort, compared to Western cohorts [8,11–15]. The median time to first episode of neuropsychiatric toxicity was within the first 2 months after initiating therapy with most events occurring within the first year. After the first year of therapy, some patients experienced neuropsychiatric events as have been documented by other authors in predominantly Caucasian cohorts [14–16]. The reported toxicities after more than 1 year of therapy may represent exacerbations of chronic undocumented toxicity or new events occurring after continual use of efavirenz.

Most studies reporting efavirenz-associated neuropsychiatric toxicity have been based on short-term follow-up of a few weeks but a cross-sectional study by Fumaz et al. among 60 patients who had been on efavirenz for a mean time of 91.1 ± 39.5 weeks found that mild and clinically tolerable neuropsychiatric disorders persisted [17]. Our data shows that even up to 90 months, some patients reported experiencing efavirenz-related neurotoxicity which did not prompt therapy changes, indicating that they may have been tolerable for the patients or that the limited repertoire of antiretrovirals available precluded modifications of an intolerable regimen. Among our cohort, insomnia, headache, dizziness, abnormal dreams and drowsiness were reported at overall frequencies of 50.0%, 7.5%, 6.7%, 5.6% and 5.2%, respectively, with higher incidences among efavirenz recipients. Rarely reported events such as seizures, cerebellar symptoms and suicidal ideations were attributed

Table 1
Baseline characteristics of patients with and without NNRTI-related neuropsychiatric events

| Characteristic | NNRTI-related neuropsychiatric events (n = 218) | No NNRTI-related neuropsychiatric events (n = 3781) | Total (n = 3999) | p-value |
|----------------|-----------------------------------------------|--------------------------------------------------|-----------------|---------|
| Age (years), median (IQR) | 40 (35–46) | 38 (32–45) | 38 (32–45) | 0.009 |
| Gender (female), n (%) | 145 (66.5) | 2577 (68.1) | 2722 (68.1) | 0.67 |
| WHO clinical stage, n (%) | | | | |
| 1 | 13 (6.0) | 258 (6.8) | 271 (6.8) | 0.58 |
| 2 | 28 (12.8) | 455 (12.3) | 483 (12.1) | |
| 3 | 123 (56.4) | 2019 (53.4) | 2142 (53.6) | |
| 4 | 27 (12.4) | 618 (16.4) | 645 (16.1) | |
| No data | 27 (12.4) | 431 (11.4) | 458 (11.4) | |
| Baseline BMI (kg/m²), median (IQR) | 19.0 (17.5–22.0) | 20.0 (18.0–22.0) | 20.0 (18.0–22.0) | 0.34 |
| Baseline CD4 count (cells/mm³), median (IQR) | 133 (51–215) | 133 (50–219) | 133 (50–219) | 0.98 |
| Baseline serum creatinine, median (IQR) | 88.4 (70.7–106.1) | 86.6 (69.0–107.0) | 86.6 (69.0–107.0) | 0.61 |
| Baseline serum ALT, median (IQR) | 31 (23–41) | 29 (20–43) | 29 (20–43) | 0.06 |
| HBsAg serology, n (%) | | | | |
| Positive | 24 (11.0) | 272 (7.2) | 296 (7.4) | 0.09 |
| Negative | 101 (46.3) | 1750 (46.3) | 1851 (46.3) | |
| Not done | 93 (42.7) | 1760 (46.5) | 1853 (46.3) | |
| NRTI backbone, n (%) | | | | |
| ZDV + 3TC | 110 (50.5) | 1791 (47.4) | 1901 (47.5) | 0.56 |
| D4T + 3TC | 108 (49.5) | 1983 (52.4) | 2091 (52.3) | |
| Others § | 0 (0.0) | 7 (0.2) | 7 (0.2) | |
| NNRTI, n (%) | | | | |
| Nevirapine | 39 (17.9) | 1583 (41.9) | 1622 (40.6) | <0.0001 |
| Efavirenz | 179 (82.1) | 2198 (58.1) | 2377 (59.4) | |

NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ZDV, zidovudine; 3TC, lamivudine; D4T, stavudine; HBsAg, hepatitis B surface antigen; BMI, body mass index. § other NRTI backbones were TDF + 3TC (n = 7), ddi + D4T (n = 1), ABC + 3TC (n = 1).

Fig. 1. A graph showing the incidence rates of neuropsychiatric symptoms attributed to toxicity over follow-up on ART among Ghanaian HIV-infected patients.
tions found in the cerebrospinal fluid [19]. Proposed mechanisms for
neuropsychiatric toxicity were the use of efavirenz, a 229% higher risk compared with nevirapine, and a low body mass index below 16 kg/m² with a 44% higher risk in adjusted analysis. This suggests that patients with low body weight may be exposed to higher concentrations of a fixed dosage of 600 mg daily and thus predispose them to neuropsychiatric toxicity. Whether the use of a lower dose (400 mg) of efavirenz, as recently shown to be effective in reducing toxicity in the Encore1 study [23], can be extrapolated to this population is debatable and further studies may be required.

Seventeen percent (17%) of patients with neuropsychiatric toxicity discontinued efavirenz due to neuropsychiatric toxicity which is higher than 4% to 10% previously reported [8–15]. This higher proportion may be due to under-reporting of milder symptoms, given the retrospective design of this study. However, the possibility also exists of higher therapeutic exposure to efavirenz in a sub-population because of the ethnicity-defined high prevalence of mutant polymorphisms in hepatic enzymes responsible for the metabolism of efavirenz, such as the CYP2B6 516 G>T polymorphisms, as has been recently shown in this population [7]. However, observations from another study in Ghana [2] and a recent meta-analysis of adverse events in patients receiving efavirenz or nevirapine as first-line therapy [24], support the WHO recommendation that efavirenz should be the preferred first-line NNRTI in Africa. Undoubtedly, the high frequency of efavirenz-associated neuropsychiatric events engendering poor adherence to a therapy with an inherently low genetic barrier to resistance could undermine the success of efavirenz-based cART as a durable first-line for resource limited settings. Indeed, these concerns coupled with recent advances with integrase inhibitor-based therapy [25–27], have led to a repositioning of the NNRTI class from a preferred to an alternative first-line regimen in the latest US DHHS guidelines [28]. For sub-Saharan Africa, studies to efavirenz by treating clinicians and these symptoms invariably re-
solved after discontinuation of efavirenz, suggesting likely causation.

The mechanisms for neuropsychiatric toxicity caused by efavirenz have recently been elucidated. There are suggestions that exposure to supra-therapeutic levels due to slower metabolism of efavirenz from the highly prevalent CYP2B6 516 G>T polymorphisms among African Americans for instance could explain why neuropsychiatric disturb-
ances are more common among them than in European American or Hispanics, as has been recently shown in this population [7]. However, observations from another study in Ghana [2] and a recent meta-analysis of adverse events in patients receiving efavirenz or nevirapine as first-line therapy [24], support the WHO recommendation that efavirenz should be the preferred first-line NNRTI in Africa. Undoubtedly, the high frequency of efavirenz-associated neuropsychiatric events engendering poor adherence to a therapy with an inherently low genetic barrier to resistance could undermine the success of efavirenz-based cART as a durable first-line for resource limited settings. Indeed, these concerns coupled with recent advances with integrase inhibitor-based therapy [25–27], have led to a repositioning of the NNRTI class from a preferred to an alternative first-line regimen in the latest US DHHS guidelines [28]. For sub-Saharan Africa, studies...
are urgently needed to evaluate the efficacy of safer and more tolerable classes of anti-retroviral agents.

5. Conclusions

In conclusion, documented neuropsychiatric toxicity on efavirenz leading to discontinuation of therapy was frequent among this cohort. Further research to evaluate the efficacy of novel and tolerable regimens as first-line ART and to determine whether a lower dose of efavirenz reduces neuropsychiatric side effects is warranted in sub-Saharan Africa.

Competing Interests

All authors declare they have no competing interests.

Authors’ Contributions

FS conceived and designed the study, completed the analyses and wrote the manuscript. MAS assisted with study analysis. DC conceived and designed the study, and wrote the manuscript. All authors read and approved the final manuscript.

Acknowledgements

The authors are grateful to all the physicians, nurses and paramedical staff involved in the care of HIV patients at the Komfo Anokye Teaching Hospital for their support. This study received financial support from an HIV Research Trust Scholarship (HIVRT12-081) to FSS and the South Tees Infectious Diseases Research Fund (E186).

References

[1] WHO. Antiretroviral therapy for HIV infection in adults and adolescents, recommendations for a public health approach 2010 revision. [http://www.int/entity/hiv/pub/ar/ada2010/en/index.html]

[2] F.S. Sarfo, M.A. Sarfo, A. Kasim, et al., The long-term effectiveness of first-line NNRTI-based antiretroviral therapy in Ghana, J Antimicrob Chemother 69 (2014) 254–261.

[3] P. deBeaudrap, J.F. Etard, F.N. Gueye, et al., Long-term efficacy and tolerance of efavirenz- and nevirapine-containing regimens in adult HIV type 1 Senegalese patients, AIDS Res. Hum. Retrovir. 24 (2008) 753–760.

[4] S.L. Walmsley, A. Antela, N. Clumeck, et al., Dolutegravir plus abacavir-lamivudine in the treatment of HIV-1 infection, N. Engl. J. Med. 369 (2013) 1807–1818.

[5] J.H. Ouyzi, J. Byobika-Tusinie, K. Ragland, et al, Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda, AIDS 21 (2007) 965–971.

[6] WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach, [http://www.who.int/hiv/pub/guidelines/ar2013/short_summary/en/June 2013].

[7] F.S. Sarfo, Y. Zhang, D. Egan, et al., Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients, J Antimicrob Chemother 69 (2014) 491–499.

[8] J.A. Perez-Molina, Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicentre prospective study in 1033 HIV-infected patients, HIV Clin Trials 3 (2002) 279–286.

[9] C.R. Fumaz, A. Tuldra, M.J. Ferrer, et al., Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens, J Acquir. Immune Defic. Syndr. 29 (2002) 244–253.

[10] European Medicines Agency. EPARs for authorised medicinal products for human use: Sustiva SmPC. [http://www.emea.europa.eu/humandocs/Humans/EPAR/sustiva/sustiva.htm]

[11] T. Hawkins, C. Geist, B. Young, et al., Comparison of neuropsychiatric side effects in an observational cohort of efavirenz- and protease inhibitor-treated patients, HIV Clin Trials 6 (2005) 187–196.

[12] S. Staszewski, J. Morales-Ramirez, K.T. Tashima, et al., Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 team, N Engl J Med 341 (1999) 1865–1873.

[13] L.O. Abah, M. Akansi, M.E. Abah, et al., Incidence and predictors of adverse drug events in an African cohort of HIV-infected adults treated with efavirenz, GERMS 5 (3) (2015) 83–91.

[14] G. Arendt, D. de Necker, H.J. von Giesen, et al., Neuropsychiatric side effects of efavirenz therapy, Expert Opin Drug Saf 6 (2007) 147–154.

[15] J.A. Muñoz-Moreno, C.R. Fumaz, M.J. Ferrer, et al., Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates, management. A neurobehavioural review, AIDS Rev 11 (2009) 103–109.

[16] M. Zaccarelli, F. Soldani, G. Luzi, et al., CNS side effects as main risk factor for efavirenz failure and transient HIV-RNA elevation, Abstracts of the Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, WA, USA, Foundation for Retrovirology and Human Health, Alexandria, VA, USA, 2002 Abstract 720-T.

[17] C.R. Fumaz, J.A. Muñoz-Moreno, J. Moltó, et al., Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence, J Acquir Immune Defic Syndr 38 (2005) 560–565.

[18] D.W. Haas, H.J. Ribaudo, R.B. Kim, et al., Pharmacogenetics of efavirenz and central nervous system side effects: an adults AIDS clinical trials group study, AIDS 18 (2004) 2391–2400.

[19] E.H. Decloedt, G. Maartens, Neuronal toxicity of efavirenz: a systematic review, Expert Opin. Drug Saf. 12 (6) (2013) 841–845.

[20] H.A. Funes, N. Apostolova, F. Alegre, et al., Neurol bioenergetics and acute mitochondrial dysfunction: a clue to understanding the central nervous system side effects of efavirenz, J Infect Dis 210 (9) (2014) 1385–1395.

[21] P.R. Purnell, H.S. Fox, Efavirenz induced neuronal autophagy and mitochondrial alterations, J Pharmacol Exp Ther 351 (2) (2014) 250–258.

[22] N. Apostolova, H.A. Funes, A. Blas-García, et al., Involvement of nitric oxide in the mitochondrial action of efavirenz: a differential effect on neurons and glial cells, J Infect Dis 211 (12) (2015) 1953–1958.

[23] ENCORE1, S. Group, R. Puls, et al., Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial, Lancet 383 (9927) (2014) 1474–1482.

[24] Z. Shubber, A. Calmy, I. Andrieux-Meyer, et al., Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis, AIDS 27 (9) (2013) 1403–1412.

[25] P.E. Sax, D. Wohl, M.T. Yin, et al., GS-US-292-0104/0111 Study Team. Tenofovir and elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 2012 Jun 30;379(9835):2439–48, doi:10.1016/S0140-6736(12)60917-9. Erratum in: Lancet. 2012 Aug25;380(9843):730.PMID: 22748591.

[26] P.E. Sax, D. Wohl, M.T. Yin, et al., GS-US-202-0104/0111 Study Team. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials, Lancet 385 (9987) (2015 Jun 27) 2606–2615, http://dx.doi.org/10.1016/S0140-6736(15)60616-X Epub 2015 Apr 15.

[27] F. Raffi, A. Rachlis, C. Brinson, et al., E/C/TAF efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials, AIDS 29 (2015 Jan 14) 167–174.

[28] DHBIS, Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, 2015 Accessed 31 August 2015 at http://aidsinfo.nih.gov/guidelines/ html/1/adult-and-adolescent-treatment-guidelines/0/.